Skip to main content

Table 3 Serum PFAS (medians, 25th–75th percentiles) according to Tanner stage, SES, age, and SDS for BMI, weight, and height

From: Associations between exposure to perfluoroalkyl substances and body fat evaluated by DXA and MRI in 109 adolescent boys

  n (%) PFOA (ng/mL) PFOS (ng/mL) PFHxS (ng/mL) PFNA (ng/mL) PFDA (ng/mL)
Median 25th-75th percentiles Median 25th-75th percentiles Median 25th-75th percentiles Median 25th-75th percentiles Median 25th-75th percentiles
Tanner stage 100           
 1 20 (20) 3.05 2.58–3.58 8.57 6.70-–1.11 0.55 0.44–0.72 1.07 0.89–1.41 0.36 0.29–0.45
 2 33 (33) 2.99 2.22–4.27 7.03 5.40–9.95 0.54 0.44–0.68 0.95 0.72–1.19 0.33 0.24–0.41
 3 29 (29) 2.46 2.07–3.18 6.23 5.79–8.09 0.47 0.41–0.68 0.77 0.66–0.99 0.27 0.23–0.32
 4 + 5 18 (18) 2.26 1.85–3.36 6.04 5.12–7.43 0.43 0.31–0.51 0.85 0.71–1.08 0.27 0.23–0.32
P-value*   0.04   0.01   0.03   0.04   0.01  
SES 108           
 1 57 (52.7) 2.74 2.74–3.42 7.42 6.17–10.19 0.51 0.44–0.70 0.92 0.73–1.13 0.32 0.25–0.37
 2–4 51 (47.2) 3.00 2.19–3.63 6.23 5.40–7.90 0.46 0.37–0.54 0.94 0.73–1.20 0.29 0.24–0.36
P-value*   0.58   0.01   0.01   0.55   0.21  
Age (years) 109           
 10–11.9 36 (33.0) 3.13 2.28–4.31 6.92 6.06–8.59 0.52 0.44–0.64 0.94 0.69–1.22 0.33 0.26–0.37
 12.0–12.9 41 (37.6) 2.56 2.16–3.53 7.12 5.54–10.44 0.46 0.39–0.66 0.95 0.77–1.18 0.32 0.25–0.38
 13.0–15 32 (29.6) 2.68 2.00–3.30 6.63 5.85–8.71 0.48 0.41–0.66 0.82 0.71–1.04 0.28 0.25–0.36
P-value*   0.14   0.85   0.30   0.53   0.48  
BMI SDS 109           
  ≤ -1 22 (20.2) 2.77 2.17–3.13 6.90 5.97–10.53 0.47 0.43–0.56 0.96 0.68–1.20 0.27 0.25–0.40
  > -1 to ≤ 0 39 (35.8) 2.79 2.09–3.31 7.83 6.03–10.0 0.51 0.41–0.70 0.95 0.74–1.14 0.34 0.27–0.37
  > 0 to ≤ 1 32 (29.4) 3.08 2.27–4.99 6.56 5.87–9.29 0.52 0.42–0.67 0.91 0.73–1.42 0.31 0.23–0.40
  > 1 16 (14.7) 2.60 1.89–3.62 5.86 4.97–6.73 0.41 0.32–0.60 0.78 0.73-–1.03 0.27 0.21–0.30
P-value*   0.39   0.01   0.25   0.66   0.06  
Weight SDS 109           
  ≤ -1 19 (17.4) 2.76 2.32–3.22 7.90 5.91–10.78 0.50 0.43–0.68 1.11 0.88–1.24 0.33 0.27–0.45
  > -1 to ≤ 0 35 (32.1) 2.90 2.19–3.39 7.91 6.12–10.45 0.52 0.43–0.65 0.95 0.72–1.14 0.34 0.27–0.37
  > 0 to ≤ 1 37 (33.9) 2.79 2.07–4.08 6.52 5.41–7.93 0.50 0.41–0.69 0.82 0.69–1.22 0.27 0.22–0.34
  > 1 18 (16.5) 2.53 1.85–3.62 6.14 5.14–7.06 0.41 0.34–0.58 0.81 0.75–1.07 0.28 0.23–0.33
P-value*   0.79   0.01   0.13   0.40   0.02  
Height SDS 109           
  ≤ -1 15 (13.8) 3.17 2.69–7.14 10.11 7.12–13.03 0.68 0.54–0.85 1.11 0.91–1.27 0.36 0.31–0.52
  > -1 to ≤ 0 33 (30.3) 2.84 2.24–3.44 7.91 5.99–10.12 0.51 0.43–0.65 0.95 0.69–1.21 0.34 0.26–0.40
  > 0 to ≤ 1 37 (33.9) 2.92 2.19–3.62 6.23 5.57–7.48 0.47 0.40–0.65 0.90 0.73–1.07 0.29 0.25–0.34
  > 1 24 (22.0) 2.37 1.89–3.06 6.32 5.31–7.13 0.43 0.38–0.54 0.79 0.63–1.09 0.26 0.21–0.33
P-value*   0.06    < 0.01   0.01   0.09   0.01  
  1. Data are presented as medians and 25–75 percentiles. SES Socioeconomic status, BMI Body mass index, SDS Standard deviation score, PFAS Polyfluoroalkyl substances, PFOA Perfluorooctanoic acid, PFOS Perfluorooctane sulfonic acid, PFHxS Perfluorohexane sulfonic acid, PFNA Perfluorononanoic acid, PFDA Perfluorodecanoic acid
  2. * Differences in PFAS concentrations between subgroups were tested using Kruskal–Wallis test. P-values < 0.05 were considered significant and highlighted in bold